Quote:
Originally Posted by cheri
Regarding CampathvClinical Trial, they say ineligible if my MDS is secondary to my AML treatment, but then they thought my AML may have started with MDS. And how do I know if I have less than 6 months?
|
Hey Cheri!
If you are looking at the NIH trial criteria, I guess the question would be whether your MDS is actual secondary MDS (i.e., probably caused by your induction chemo) or if you are thought to have MDS now because your blast count has decreased enough that your disease has just fallen out of the AML category.
Do you know your IPSS score? Generally, immunosuppressant therapy (with ATG or Campath) has been more successful with lower risk patients.
Take care!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at
www.greghankins.com